Skip to main content
Genome&Company logo

Genome&Company — Investor Relations & Filings

Ticker · 314130 ISIN · KR7314130006 KO Manufacturing
Open in API
Filings indexed 427 across all filing types
Latest filing 2025-12-18 Major Shareholding Noti…
Country KR South Korea
Listing KO 314130

About Genome&Company

http://genomecom.co.kr/

Genome&Company is a clinical-stage biopharmaceutical company focused on the discovery and development of innovative therapeutics. The company's research and development pipeline is centered on two primary platforms: microbiome-based pharmaceuticals and novel immune checkpoint inhibitors for immuno-oncology. Its drug candidates are derived from its proprietary microbiome platform and are aimed at treating a range of diseases, with a significant focus on cancer. In addition to its pharmaceutical programs, the company develops and markets consumer healthcare products, including dietary supplements and cosmeceuticals, leveraging its expertise in microbes and probiotics.

Recent filings

Filing Released Lang Actions
주식등의대량보유상황보고서(약식)
Major Shareholding Notification Classification · 100% confidence The document is a 'Report of Large Shareholding' (주식등의 대량보유상황보고서), which is a standard regulatory filing in South Korea (often referred to as a 5% rule filing). It details changes in share ownership by a specific entity (Paratus Newnormal TCB Private Equity Fund) in a listed company (Genome & Company). This type of filing is specifically categorized as a 'Major Shareholding Notification' (MRQ) in the provided schema.
2025-12-18 Korean
주주명부폐쇄기간또는기준일설정
Regulatory Filings Classification · 95% confidence The document is a short regulatory announcement regarding the setting of a record date and shareholder register closure for an upcoming Annual General Meeting. It does not contain the full meeting materials or proxy statements, but rather serves as a formal notice of the administrative procedure for shareholder identification. Given its nature as a regulatory notification of a corporate event, it fits best under the RNS category.
2025-12-16 Korean
주식등의대량보유상황보고서(일반)
Major Shareholding Notification Classification · 100% confidence The document is titled '주식등의 대량보유상황보고서(일반)' which translates to 'Report on Large Shareholding Status (General)'. It contains detailed information about the number of shares held, changes in shareholding, relationships of shareholders, and reasons for changes such as repayment of stock collateral loans. The document references specific dates and shareholding percentages, and it is addressed to regulatory bodies such as the Financial Services Commission and the Korea Exchange. This type of filing corresponds to notifications about major shareholding changes, which aligns with the category 'Major Shareholding Notification' (Code: MRQ). The document is substantive and not merely an announcement or certification, and it is not a general regulatory filing or other report type. Therefore, the correct classification is MRQ with high confidence.
2025-10-28 Korean
전환사채(해외전환사채포함)발행후만기전사채취득
Capital/Financing Update Classification · 95% confidence The document is a detailed announcement regarding the acquisition of bonds before maturity, specifically convertible bonds (including overseas convertible bonds). It includes specific financial details such as bond types, issuance dates, acquisition amounts, and reasons for acquisition. The document is short (1353 characters) and focuses on a specific capital transaction event rather than a comprehensive financial report or earnings release. It does not contain full financial statements or management discussion but rather a specific update on bond acquisition and related capital activity. Therefore, it fits best under the category of Capital/Financing Update (CAP).
2025-10-10 Korean
주요사항보고서(타법인주식및출자증권양도결정)
M&A Activity Classification · 100% confidence The document is a 'Major Report' (주요사항보고서) filed with the Financial Supervisory Service/Korea Exchange regarding the decision to dispose of shares in another corporation (타법인 주식 및 출자증권 양도결정). This is a specific regulatory disclosure required for material corporate events. Since it does not fit into the specific categories like M&A (which usually refers to full company takeovers) or other specialized categories, it falls under the general regulatory filing category.
2025-08-21 Korean
반기보고서 (2025.06)
Interim / Quarterly Report Classification · 100% confidence The document is a '반기보고서' (Semi-annual Report) for the company 'Genome&Company' (지놈앤컴퍼니) covering the period from January 1, 2025, to June 30, 2025. It contains detailed financial information, business operations, management discussions, and corporate governance details, which aligns with the definition of an Interim/Quarterly Report (IR). H1 2025
2025-08-14 Korean

Browse filings by year

9 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.